Skip to main content
Premium Trial:

Request an Annual Quote

Denmark s Exiqon A/S Takes $3 Million Funding

NEW YORK, February 12 -- Exiqon A/S of Copenhagen, Denmark, today announced a fourth-round funding of $3 million.

 

The company said the funding follows a restructuring and layoffs. Details were not available. Investors in the round include Danske Bank, LD, Nobel Group, Scandinavian Life Sciences Venture, and Teknoinvest, the company said. Exiqon will seek an additional $1.5 million in capital, the company said in a statement.

 

The company is commercializing the synthesis and applications of LNA, a novel high-affinity DNA analog with the promise of creating specificity and affinity for conventional DNA-based techniques, the company said.

 

The firm is hoping that the funding, and the restructuring, will help it bridge the gap between development and commercialization, or "until sufficient license revenues are secured by first quarter 2004," the company said in a statement.

 

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.